CORDIS
EU research results

CORDIS

English EN

Biochemically Equivalent Substitutive Technology for Stem Cells

Objective

Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potential avenues for the introduction of unknown or known pathogens with the capacity to infect transplant recipients thereby becoming communicable to the general population. Especially concerning is the opportunity for transmission of potentially lethal diseases across vertebrate species for which there are no known cures. The propensity of primitive stem cell populations to spontaneously differentiate is an added challenge which generally necessitates cumbersome manipulation of cells by skilled operators involving daily assessment, media replenishment and or cell passaging by physical dissociation. Realising the promise of stem cells and their derivatives for clinical and industrial applications therefore requires the evolution of new paradigms for cell culture which maximise chemical definition, minimise the involvement of skilled operators, and offer non-invasive modulation of cells by biocompatible means. The aim of this proposal is to discover and integrate with established and new cell culture technology, synthetic and non-vertebrate derived purified molecules with a capacity to mimic the functional properties of crude biological reagents currently used to control the behaviour of embryonic and adult stem cells, most notably affecting self-renewal, pluripotency, lineage specification and stability following cryopreservation. These will be validated to deliver new culture paradigms designed for compliance with Good Manufacturing Practice Standards necessary for the delivery of clinical grade cells for therapeutic use.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE UNIVERSITY OF EDINBURGH

Address

Old College, South Bridge
Eh8 9yl Edinburgh

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 372 211

Administrative Contact

Angela Noble (Ms.)

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

Roslin Cells Ltd.

United Kingdom

EU Contribution

€ 107 582

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 509 600

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 240 534

UNIVERSITATSKLINIKUM BONN

Germany

EU Contribution

€ 447 600

BIONEER A/S

Denmark

EU Contribution

€ 154 950

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 98 400

GLYCOMAR LIMITED

United Kingdom

EU Contribution

€ 68 190

Project information

Grant agreement ID: 223410

Status

Closed project

  • Start date

    1 July 2009

  • End date

    31 December 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 983 495,40

  • EU contribution

    € 2 999 067

Coordinated by:

THE UNIVERSITY OF EDINBURGH

United Kingdom